Anixa Biosciences (ANIX) 10-Q 1 Sep 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Jul. 31, 2021	Sep. 01, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jul. 31, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--10-31
Entity File Number	001-37492
Entity Registrant Name	ANIXA BIOSCIENCES, INC.
Entity Central Index Key	0000715446
Entity Tax Identification Number	11-2622630
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	3150 Almaden Expressway
Entity Address, Address Line Two	Suite 250
Entity Address, City or Town	San Jose
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95118
City Area Code	(408)
Local Phone Number	708-9808
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	ANIX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		29,949,905

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jul. 31, 2021	Oct. 31, 2020
Current assets:
Cash and cash equivalents	$ 27,222,190	$ 6,417,061
Short-term investments	9,399,784	2,640,000
Prepaid expenses and other current assets	430,006	311,563
Total current assets	37,051,980	9,368,624
Operating lease right-of-use asset	10,411	54,340
Other assets		30,000
Total assets	37,062,391	9,452,964
Current liabilities:
Accounts payable	207,733	232,368
Accrued expenses	989,724	901,025
Operating lease liability	10,567	55,198
Total current liabilities	1,208,024	1,188,591
Shareholders’ equity:
Preferred stock, value
Common stock, par value $.01 per share; 100,000,000 shares authorized; 29,949,905 and 24,248,695 shares issued and outstanding, respectively	299,499	242,486
Additional paid-in capital	236,944,345	200,354,488
Accumulated deficit	(200,776,749)	(191,835,618)
Total shareholders’ equity	36,467,095	8,761,356
Noncontrolling interest (Note 1)	(612,728)	(496,983)
Total equity	35,854,367	8,264,373
Total liabilities and equity	37,062,391	9,452,964
Series A Convertible Preferred Stock [Member]
Shareholders’ equity:
Preferred stock, value

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jul. 31, 2021	Oct. 31, 2020
Preferred stock, par value	$ 100	$ 100
Preferred stock, shares authorized	19,860	19,860
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	29,949,905	24,248,695
Common stock, shares outstanding	29,949,905	24,248,695
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 100	$ 100
Preferred stock, shares authorized	140	140
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudit - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2021	Jul. 31, 2020	Jul. 31, 2021	Jul. 31, 2020
Income Statement [Abstract]
Revenue			$ 512,500
Operating costs and expenses:
Inventor royalties, contingent legal fees, litigation and licensing expenses			385,002
Research and development expenses (including non-cash share-based compensation expenses of $1,687,754, $394,842, $2,425,136 and $1,250,497, respectively)	2,166,622	1,254,131	4,016,449	3,973,509
General and administrative expenses (including non-cash share-based compensation expenses of $1,499,572, $646,957, $2,799,561 and $1,922,722, respectively)	2,221,614	1,181,838	5,169,698	3,762,466
Total operating costs and expenses	4,388,236	2,435,969	9,571,149	7,735,975
Loss from operations	(4,388,236)	(2,435,969)	(9,058,649)	(7,735,975)
Other expense		(148,084)		(148,084)
Interest income	626	7,266	1,773	32,707
Net loss	(4,387,610)	(2,576,787)	(9,056,876)	(7,851,352)
Less: Net loss attributable to noncontrolling interest	(53,621)	(15,103)	(115,745)	(57,032)
Net loss attributable to common shareholders	$ (4,333,989)	$ (2,561,684)	$ (8,941,131)	$ (7,794,320)
Net loss per common share attributable to common shareholders: Basic and diluted	$ (0.14)	$ (0.11)	$ (0.32)	$ (0.36)
Weighted average common shares outstanding: Basic and diluted	30,455,340	23,165,066	28,090,163	21,678,608

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudit (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2021	Jul. 31, 2020	Jul. 31, 2021	Jul. 31, 2020
Research and Development Expense [Member]
Share-based Payment Arrangement, Expense	$ 1,687,754	$ 394,842	$ 2,425,136	$ 1,250,497
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expense	$ 1,499,572	$ 646,957	$ 2,799,561	$ 1,922,722

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total Shareholders' Equity [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Oct. 31, 2019	$ 203,317	$ 186,849,299	$ (181,817,263)	$ 5,235,353	$ (422,975)	$ 4,812,378
Beginning balance, shares at Oct. 31, 2019	20,331,754
Stock option compensation to employees and directors		3,016,305		3,016,305		3,016,305
Stock options issued to consultants		156,914		156,914		156,914
Common stock issued upon exercise of stock options	$ 511	121,759		122,270		122,270
Common stock issued upon exercise of stock options, shares	51,100
Common stock issued in at-the-market offering, net of offering expenses	$ 32,613	7,833,427		7,866,040		7,866,040
Common stock issued in at-the-market offering, net of offering expenses, shares	3,261,282
Common stock issued pursuant to employee stock purchase plan	$ 96	15,356		15,452		15,452
Common stock issued pursuant to employee stock purchase plan, shares	9,618
Net loss			(7,794,320)	(7,794,320)	(57,032)	(7,851,352)
Ending balance, value at Jul. 31, 2020	$ 236,537	197,993,060	(189,611,583)	8,618,014	(480,007)	8,138,007
Ending balance, shares at Jul. 31, 2020	23,653,754
Beginning balance, value at Apr. 30, 2020	$ 214,793	192,122,260	(187,049,899)	5,287,154	(464,904)	4,822,250
Beginning balance, shares at Apr. 30, 2020	21,479,335
Stock option compensation to employees and directors		997,094		997,094		997,094
Stock options issued to consultants		44,705		44,705		44,705
Common stock issued upon exercise of stock options	$ 72	18,468		18,540		18,540
Common stock issued upon exercise of stock options, shares	7,200
Common stock issued in at-the-market offering, net of offering expenses	$ 21,672	4,810,533		4,832,205		4,832,205
Common stock issued in at-the-market offering, net of offering expenses, shares	2,167,219
Net loss			(2,561,684)	(2,561,684)	(15,103)	(2,576,787)
Ending balance, value at Jul. 31, 2020	$ 236,537	197,993,060	(189,611,583)	8,618,014	(480,007)	8,138,007
Ending balance, shares at Jul. 31, 2020	23,653,754
Beginning balance, value at Oct. 31, 2020	$ 242,486	200,354,488	(191,835,618)	8,761,356	(496,983)	8,264,373
Beginning balance, shares at Oct. 31, 2020	24,248,695
Stock option compensation to employees and directors		4,803,515		4,803,515		4,803,515
Common stock issued upon exercise of stock options	$ 1,075	292,529		293,604		$ 293,604
Common stock issued upon exercise of stock options, shares	107,451					44,000
Common stock issued in at-the-market offering, net of offering expenses	$ 28,064	10,805,651		10,833,715		$ 10,833,715
Common stock issued in at-the-market offering, net of offering expenses, shares	2,806,410
Common stock issued pursuant to employee stock purchase plan	$ 16	2,984		3,000		3,000
Common stock issued pursuant to employee stock purchase plan, shares	1,634
Common stock issued in a public offering, net of offering expenses of $2,208,150	$ 42,858	20,248,996		20,291,854		20,291,854
Common stock issued in a public offering, net of offering expenses, shares	4,285,715
Expired restricted stock award to employee	$ (15,000)	15,000
Expired restricted stock award to employee, shares	(1,500,000)
Stock options and warrants issued to consultants		421,182		421,182		421,182
Net loss			(8,941,131)	(8,941,131)	(115,745)	(9,056,876)
Ending balance, value at Jul. 31, 2021	$ 299,499	236,944,345	(200,776,749)	36,467,095	(612,728)	35,854,367
Ending balance, shares at Jul. 31, 2021	29,949,905
Beginning balance, value at Apr. 30, 2021	$ 314,499	233,742,019	(196,442,760)	37,613,758	(559,107)	37,054,651
Beginning balance, shares at Apr. 30, 2021	31,449,905
Stock option compensation to employees and directors		3,047,877		3,047,877		3,047,877
Expired restricted stock award to employee	$ (15,000)	15,000
Expired restricted stock award to employee, shares	(1,500,000)
Stock options and warrants issued to consultants		139,449		139,449		139,449
Net loss			(4,333,989)	(4,333,989)	(53,621)	(4,387,610)
Ending balance, value at Jul. 31, 2021	$ 299,499	$ 236,944,345	$ (200,776,749)	$ 36,467,095	$ (612,728)	$ 35,854,367
Ending balance, shares at Jul. 31, 2021	29,949,905

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical) - USD ($)	3 Months Ended	9 Months Ended
	Jul. 31, 2020	Jul. 31, 2021	Jul. 31, 2020
Statement of Stockholders' Equity [Abstract]
Expenses of the at-the-market offering	$ 155,776	$ 340,775	$ 314,072
Expenses of the public offering		$ 2,208,150

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2021	Jul. 31, 2020	Jul. 31, 2021	Jul. 31, 2021	Jul. 31, 2020
Reconciliation of net loss to net cash used in operating activities:
Net loss	$ (4,387,610)	$ (2,576,787)		$ (9,056,876)	$ (7,851,352)
Stock option compensation to employees and directors				4,803,515	3,016,305
Stock options and warrants issued to consultants				421,182	156,914
Depreciation of property and equipment					38,276
Loss on disposal of property and equipment					148,084
Gain on sale of equipment				(5,447)
Amortization of operating lease right-of-use asset				43,929	38,317
Change in operating assets and liabilities:
Receivables					60,577
Prepaid expenses and other current assets				(118,443)	(4,870)
Accounts payable				(24,635)	(246,522)
Accrued expenses				88,699	(79,781)
Operating lease liability				(44,631)	(37,537)
Net cash used in operating activities				(3,892,707)	(4,761,589)
Cash flows from investing activities:
Disbursements to acquire short-term investments				(10,399,784)	(5,510,000)
Proceeds from maturities of short-term investments				3,640,000	4,720,000
Purchase of property and equipment					(15,791)
Proceeds from sale of equipment				35,447
Net cash used in investing activities				(6,724,337)	(805,791)
Cash flows from financing activities:
Gross proceeds from sale of common stock in a public offering				22,500,004
Expenses of the public offering			$ (2,208,150)	(2,208,150)
Gross proceeds from sale of common stock in an at-the-market offering				11,174,490	8,180,112
Expenses of the at-the-market offering				(340,775)	(314,072)
Proceeds from sale of common stock pursuant to employee stock purchase plan				3,000	15,452
Proceeds from exercise of stock options				293,604	122,270
Net cash provided by financing activities				31,422,173	8,003,762
Net increase in cash and cash equivalents				20,805,129	2,436,382
Cash and cash equivalents at beginning of period				6,417,061	3,491,625
Cash and cash equivalents at end of period	$ 27,222,190	$ 5,928,007	$ 27,222,190	27,222,190	5,928,007
Supplemental cash flow information:
Cash proceeds from interest income				1,675	38,930
Supplemental disclosure of non-cash financing activity:
Fair value of warrants issued in connection with the public offering				$ 1,040,700

BUSINESS AND FUNDING

BUSINESS AND FUNDING	9 Months Ended
	Jul. 31, 2021
Accounting Policies [Abstract]
BUSINESS AND FUNDING	1. BUSINESS AND FUNDING Description of Business As used herein, “we,” “us,” “our,” the “Company” or “Anixa” means Anixa Biosciences, Inc. and its consolidated subsidiaries. Our primary operations involve developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. Our therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (“CAR-T”) technology, initially focused on treating ovarian cancer, and discovery and ultimately development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Our vaccine programs include the development of a vaccine against breast cancer, specifically triple negative breast cancer (“TNBC”), the most lethal form of the disease, and a vaccine against ovarian cancer. Our subsidiary, Certainty Therapeutics, Inc. (“Certainty”), is developing immuno-therapy drugs against cancer. Certainty holds an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Wistar Institute (“Wistar”) relating to Wistar’s CAR-T technology. We have initially focused on the development of a treatment for ovarian cancer, but we may also pursue applications of the technology for the development of treatments for additional solid tumors. The license agreement requires Certainty to make certain cash and equity payments to Wistar upon achievement of specific development milestones. With respect to Certainty’s equity obligations to Wistar, Certainty issued to Wistar shares of its common stock equal to five percent ( 5 Certainty, in collaboration with the H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”), is advancing toward human clinical testing its CAR-T technology for treating ovarian cancer. We submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) in March 2021. In April 2021, the FDA informed us that they needed additional information before allowing us to proceed with the clinical trial. In May 2021, the FDA provided us with the details of their information request. Through an iterative process with the FDA, we responded to their information requests and in August 2021, we received authorization from the FDA to commence enrollment and treatment of patients in a Phase 1 clinical trial. We are performing the activities necessary to prepare for treatment of patients in the Phase 1 clinical trial, and we anticipate treating the first enrolled patient in early 2022. In April 2020, we entered into a collaboration with OntoChem GmbH (“OntoChem”), to discover and ultimately develop anti-viral drug candidates against COVID-19. Through this collaboration, we utilized advanced computational methods, machine learning, and molecular modeling techniques to perform in silico The screening process resulted in the identification of multiple compounds that could potentially disrupt critical enzymes of the virus. Several of these compounds were synthesized and tested in in vitro In May 2021, after completion of the aforementioned animal studies, OntoChem assigned its rights and obligations related to this collaboration to MolGenie GmbH (“MolGenie”), a company spun-out from OntoChem focused on drug discovery and development. In August 2021, in an attempt to evaluate whether our compounds might be effective against the Delta variant of SARS-CoV-2, we undertook an analysis of certain enzyme mutations in the Delta variant. We note that the Delta variant is characterized by mutations in the spike protein of the virus. Corresponding to the mutations in the spike protein, we found some of the Delta variants exhibited a mutation in the enzyme that is our target. Sequence analysis of several Delta variant samples demonstrated that the resultant enzyme mutation indicates that our novel compounds could be stronger inhibitors of the Delta variant that the original version of the virus. We hold an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Cleveland Clinic Foundation (“Cleveland Clinic”) relating to certain breast cancer vaccine technology developed at Cleveland Clinic. We are working in collaboration with Cleveland Clinic to develop a method to vaccinate women against contracting breast cancer, focused specifically on TNBC. A specific protein, alpha-lactalbumin, has been identified that is only expressed during lactation in a healthy woman’s mammary tissue. This protein disappears when the woman is no longer lactating, but reappears in many forms of breast cancer, especially TNBC. Studies have shown that vaccinating against this protein prevents breast cancer in mice. In December 2020, we received authorization from the FDA to commence enrollment and treatment of patients in a Phase 1a clinical trial. We are performing the activities necessary to prepare for treatment of patients in the Phase 1a clinical trial, and we anticipate treating the first enrolled patient in September 2021. In November 2020, we executed a license agreement with Cleveland Clinic pursuant to which the Company was granted an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by Cleveland Clinic relating to certain ovarian cancer vaccine technology. This technology pertains to the use of vaccines for the treatment or prevention of ovarian cancers which express the anti-Mullerian hormone receptor II protein containing an extracellular domain (“AMHR2-ED”). In healthy tissue, this protein regulates growth and development of egg-containing follicles in the ovary. While expression of AMHR2-ED naturally and markedly declines after menopause, this protein is expressed at high levels in the ovaries of postmenopausal women with ovarian cancer. Researchers at Cleveland Clinic believe that a vaccine targeting AMHR2-ED could prevent the occurrence of ovarian cancer. We entered into a joint development agreement with Cleveland Clinic, to advance this vaccine technology toward human clinical testing. In May 2021, Cleveland Clinic was granted an award for our ovarian cancer vaccine technology by the National Cancer Institute’s (“NCI”) PREVENT program. The NCI is a part of the National Institutes of Health. The PREVENT program is a peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. The scientific and financial resources of the PREVENT program will be used for our ovarian cancer vaccine technology to perform virtually all pre-clinical research and development, manufacturing and IND-enabling studies. This work will be performed at NCI facilities, by NCI scientific staff and with NCI financial resources and will require no material financial expenditures by the Company, nor the transfer of any rights to the Company’s assets. Over the next several quarters, we expect the development of our breast and ovarian cancer vaccines, our COVID-19 therapeutic program and Certainty’s CAR-T technology to be the primary focus of the Company. As part of our legacy operations, the Company remains engaged in limited patent licensing activities regarding the Cchek™ liquid biopsy platform (operations for which were suspended in July 2020), as well as in the area of encrypted audio/video conference calling. We do not expect these activities to be a significant part of the Company’s ongoing operations, nor do we expect these activities to require material financial resources or attention of senior management. Over the past several years, our revenue, if any, was derived from technology licensing and the sale of patented technologies, including revenue from the settlement of litigation. We have not generated any revenue to date from our therapeutics or vaccine programs. In addition, while we pursue our therapeutics and vaccine programs, we may also make investments in and form new companies to develop additional emerging technologies. We do not expect to begin generating revenue with respect to any of our current therapy or vaccine programs in the near term. We hope to achieve a profitable outcome by eventually licensing our technologies to large pharmaceutical companies that have the resources and infrastructure in place to manufacture, market and sell our technologies as therapeutics or vaccines. The eventual licensing of any of our technologies may take several years, if it is to occur at all, and may depend on positive results from human clinical trials. Funding and Management’s Plans Based on currently available information as of September 1, 2021, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows will be sufficient to fund our activities for at least the next twelve months. We have implemented a business model that conserves funds by collaborating with third parties to develop our technologies. However, our projections of future cash needs and cash flows may differ from actual results. If current cash on hand, cash equivalents, short-term investments and cash that may be generated from our business operations are insufficient to continue to operate our business, or if we elect to invest in or acquire a company or companies or new technology or technologies that are synergistic with or complementary to our technologies, we may be required to obtain more working capital. During the nine months ended July 31, 2021, we raised approximately $ 20,292,000 4,285,715 10,834,000 2,806,410 Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and disclosures required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures included in our Annual Report on Form 10-K for the year ended October 31, 2020. The accompanying October 31, 2020 condensed consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by US GAAP. The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of July 31, 2021, and results of operations and cash flows for the interim periods represented. The results of operations for the nine months ended July 31, 2021 are not necessarily indicative of the results to be expected for the entire year. Noncontrolling Interest Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the nine months ended July 31, 2021: SCHEDULE OF CHANGES IN NONCONTROLLING INTEREST Balance, October 31, 2020 $ (496,983 ) Net loss attributable to noncontrolling interest (115,745 ) Balance, July 31, 2021 $ (612,728 ) Revenue Recognition Our revenue has been derived solely from technology licensing and the sale of patented technologies. Revenue is recognized upon transfer of control of intellectual property rights and satisfaction of other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive. We follow the accounting guidance of Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. In accordance with ASC 606 we are required to make certain judgments and estimates in connection with the accounting for revenue. Such judgments and estimates may include determining the existence of a contract and identifying each party’s rights and obligations to transfer goods and services, identifying the performance obligations in the contract, determining the transaction price and allocating the transaction price to separate performance obligations, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services and evaluating whether a license transfers to a customer at a point in time or over time. Our revenue arrangements provide for the payment, within 30 days of execution of the agreement, of contractually determined, one-time, paid-up license fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we have no further obligations with respect to the granted intellectual property rights, including no obligation to maintain or upgrade the technology, or provide future support or services. Licensees obtained control of the intellectual property rights they have acquired upon execution of the agreement. Accordingly, the performance obligations from these agreements were satisfied and 100% of the revenue was recognized upon the execution of the agreements. Cost of Revenues Cost of revenues include the costs and expenses incurred in connection with our patent licensing and enforcement activities, including inventor royalties paid to original patent owners, contingent legal fees paid to external counsel, other patent-related legal expenses paid to external counsel and licensing and enforcement related research, consulting and other expenses paid to third-parties. These costs are included under the caption “Operating costs and expenses” in the accompanying condensed consolidated statements of operations. Research and Development Expenses Research and development expenses, consisting primarily of employee compensation, payments to third parties for research and development activities and other direct costs associated with developing immuno-therapy drugs against cancer, preventative cancer vaccines and anti-viral drug candidates for COVID-19, are expensed in the accompanying condensed consolidated financial statements in the period incurred.

PUBLIC OFFERING

PUBLIC OFFERING	9 Months Ended
	Jul. 31, 2021
Public Offering
PUBLIC OFFERING	2. PUBLIC OFFERING On March 25, 2021, the Company completed a public offering in which we sold an aggregate of 4,285,715 15.8 5.25 20,292,000 March 22, 2026 300,000 6.5625

STOCK BASED COMPENSATION

STOCK BASED COMPENSATION	9 Months Ended
	Jul. 31, 2021
Share-based Payment Arrangement [Abstract]
STOCK BASED COMPENSATION	3. STOCK BASED COMPENSATION The Company maintains stock equity incentive plans under which the Company grants incentive stock options, non-qualified stock options, stock appreciation rights, stock awards, performance awards, or stock units to employees, directors and consultants. Stock Option Compensation Expense The compensation cost for service-based stock options granted to employees and directors is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one four years 1,066,000 997,000 2,822,000 3,016,000 For stock options granted to employees and directors that vest based on market conditions, such as the trading price of the Company’s common stock exceeding certain price targets, we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period (median time to vest). On May 8, 2018, we issued market condition options to purchase 1,500,000 5.00 8.00 May 31, 2021 three seven 500,000 5.00 twenty On June 1, 2021, our Chairman, President and Chief Executive Officer and our Chief Operating Officer and Chief Financial Officer were awarded options for 2,000,000 shares and 100,000 shares of common stock, respectively, that vest in four equal installments upon the Company’s share price achieving targets ranging from $ 5.00 to $ 8.00 per share, with implied service periods of three to fifteen months. The assumptions used in the Monte Carlo Simulation for the June 1, 2021 grants were stock price on date of grant of $ 4.02 , contract term of 10 years, expected volatility of 75 % and risk-free interest rate of 1.62 %. We recorded stock-based compensation expense related to market condition stock options of approximately $ 1,981,000 for both the three and nine month periods ended July 31, 2021. We did not record any market condition stock-based compensation expense for these grants during the three and nine month periods ended July 31, 2020. As of July 31, 2021, the unrecognized compensation cost related to market condition stock options was approximately $ 4,528,000 which will be recognized over future periods through the fourth quarter of fiscal 2022. The compensation cost for service-based stock options granted to consultants is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to three years. We recorded stock-based consulting expense related to stock options granted to consultants of approximately $ 139,000 45,000 326,000 157,000 Stock Option Plans During the nine months ended July 31, 2021, we had two stock option plans: the Anixa Biosciences, Inc. 2010 Share Incentive Plan (the “2010 Share Plan”) and the Anixa Biosciences, Inc. 2018 Share Incentive Plan (the “2018 Share Plan”), which were adopted by our Board of Directors on July 14, 2010 and January 25, 2018, respectively. The 2018 Share Plan was approved by our shareholders on March 29, 2018. Further, we had an additional stock option plan: the Anixa Biosciences, Inc. 2003 Share Incentive Plan (the “2003 Share Plan”), under which all outstanding options expired during the nine months ended July 31, 2020. Stock Option Activity During the three months ended July 31, 2021 and 2020, we granted options to purchase 2,990,000 0 4,370,000 800,000 2.83 5.30 0 7,200 0 19,000 107,451 7,937 51,100 294,000 122,000 2003 Share Plan The 2003 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. In accordance with the provisions of the 2003 Share Plan, the plan terminated with respect to the ability to grant future awards on April 21, 2013. Information regarding the 2003 Plan for the nine months ended July 31, 2020 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Options outstanding at October 31, 2019 400 $ 17.00 Granted - $ - Exercised                  - $ - Forfeited/Expired (400 ) $ 17.00 Options outstanding and exercisable at - $ - 0 $ - 0 Options outstanding at July 31, 2020 - $ - $ - Options exercisable at July 31, 2020 - $ - $ - 2010 Share Plan The 2010 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. In accordance with the provisions of the 2010 Share Plan, the plan terminated with respect to the ability to grant future awards on July 14, 2020. Information regarding the 2010 Share Plan for the nine months ended July 31, 2021 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Options outstanding at October 31, 2020 1,907,534 $ 2.82 Exercised                  (37,500 ) $ 2.40 Forfeited/Expired (10,400 ) $ 4.57 Options outstanding and exercisable at July 31, 2021 1,859,634 $ 2.82 $ 3,138,347 The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of July 31, 2021: SCHEDULE OF OUTSTANDING AND EXERCISABLE Number And Exercisable Weighted Average (in years) Weighted $ 0 $ .67 2.30 527,500 4.80 $ 1.54 $ 2.58 3.13 818,000 2.65 $ 2.80 $ 3.46 5.30 514,134 6.75 $ 4.16 Information regarding the 2010 Share Plan for the nine months ended July 31, 2020 is as follows: Shares Weighted Average Exercise Price Per Share Aggregate Options outstanding at October 31, 2019 1,998,668 $ 2.80 Exercised (51,100 ) $ 2.39 Forfeited/Expired (20,534 ) $ 1.72 Options outstanding at July 31, 2020 1,927,034 $ 2.82 $ 731,670 Options exercisable at July 31, 2020 1,772,034 $ 2.84 $ 630,120 The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of July 31, 2020: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 0.67 2.30 549,000 5.70 $ 1.57 494,000 5.56 $ 1.64 $ 2.58 3.13 846,000 3.05 $ 2.79 846,000 3.41 $ 2.79 $ 3.46 5.75 532,034 7.45 $ 4.16 432,034 7.33 $ 4.33 2018 Share Plan The 2018 Share Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. As of July 31, 2021, the 2018 Share Plan had 1,257,937 Information regarding the 2018 Share Plan for the nine months ended July 31, 2021 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Intrinsic Value Options outstanding at October 31, 2020 4,346,661 $ 3.69 Granted 4,370,000 $ 3.79 Exercised (33,888 ) $ 3.81 Forfeited/Expired (1,392,781 ) $ 3.70 Options outstanding at July 31, 2021 7,289,992 $ 3.74 $ 5,164,696 Options exercisable at July 31, 2021 2,914,586 $ 3.64 $ 2,328,335 The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of July 31, 2021: SCHEDULE OF OUTSTANDING AND EXERCISABLE Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 2.09 3.70 2,975,000 7.90 $ 3.28 2,047,360 7.25 $ 3.49 $ 3.84 5.30 4,314,992 8.95 $ 4.06 867,226 7.33 $ 3.99 Information regarding the 2018 Share Plan for the nine months ended July, 2020 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Intrinsic Value Options outstanding at October 31, 2019 3,935,000 $ 3.74 Granted 800,000 $ 3.85 Forfeited/Expired (258,376 ) $ 3.86 Options outstanding at July 31, 2020 4,476,624 $ 3.76 $ - 0 Options exercisable at July 31, 2020 2,403,014 $ 3.76 $ - 0 The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of July 31, 2020: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 3.70 3,100,000 7.78 $ 3.70 1,700,000 7.78 $ 3.70 $ 3.84 4.61 1,376,624 7.55 $ 3.89 703,014 6.15 $ 3.90 Non-Plan Options In addition to options granted under stock option plans, during the years ended October 31, 2012 and 2013, the Board of Directors approved the grant of stock options to certain employees and directors (the “Non-Plan Options”). Information regarding Non-Plan Options for the nine months ended July 31, 2021 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Options outstanding at October 31, 2020 1,698,000 $ 2.58 Exercised (44,000 ) $ 2.58 Options outstanding and exercisable at 1,654,000 $ 2.58 $ 3,051,630 The following table summarizes information about Non-Plan Options outstanding and exercisable as of July 31, 2021: SCHEDULE OF OUTSTANDING AND EXERCISABLE Range of Number Weighted Average Remaining Contractual Life Weighted $ 2.58 1,654,000 1.06 $ 2.58 Information regarding Non-Plan Options for the nine months ended July 31, 2020 is as follows: Shares Weighted Aggregate Intrinsic Value Options outstanding at October 31, 2019 1,698,000 $ 2.58 Options outstanding and exercisable at 1,698,000 $ 2.58 $ 348,000 The following table summarizes information about Non-Plan Options outstanding and exercisable as of July 31, 2020: Range of Number Weighted Average Weighted $ 2.58 1,698,000 2.00 $ 2.58 Stock Awards On May 8, 2018, a restricted stock award of 1,500,000 11.00 May 31, 2021 Employee Stock Purchase Plan The Company maintains the Anixa Biosciences, Inc. Employee Stock Purchase Plan which permits eligible employees to purchase shares at not less than 85 1,634 9,618 3,000 15,000 Warrants On October 30, 2020 we issued a warrant, expiring on October 30, 2025 60,000 2.06 five -0- 96,000 no As discussed in Note 2, in connection with the March 25, 2021 public offering we issued to certain designees of the underwriter, as compensation, warrants to purchase 300,000 6.5625 March 22, 2026 No As of July 31, 2021, we also had warrants outstanding to purchase 500,000 5.03 November 30, 2021

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Jul. 31, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	4. FAIR VALUE MEASUREMENTS US GAAP defines fair value and establishes a framework for measuring fair value. We have categorized our financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. Financial assets and liabilities recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows: Level 1 - Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which we have the ability to access at the measurement date. Level 2 - Financial assets and liabilities whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets. Level 3 – Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset and liabilities. The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of July 31, 2021: SCHEDULE OF FAIR VALUE MEASUREMENTS Level 1 Level 2 Level 3 Total Money market funds: Cash and cash equivalents $ 26,807,696 $ - $ - $ 26,807,696 Certificates of deposit: Cash and cash equivalents 250,000 - - 250,000 Short-term investments - 1,000,000 - 1,000,000 Treasury bills and bonds: Short-term investments - 8,399,784 - 8,399,784 Total financial assets $ 27,057,696 $ 9,399,784 $ - $ 36,457,480 The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2020: Level 1 Level 2 Level 3 Total Money market funds: Cash and cash equivalents $ 3,902,292 $ - $ - $ 3,902,292 Certificates of deposit: Cash and cash equivalents 2,250,000 - - 2,250,000 Short-term investments - 2,640,000 - 2,640,000 Total financial assets $ 6,152,292 $ 2,640,000 $ - $ 8,792,292 Our non-financial assets that are measured on a non-recurring basis include our other assets which are measured using fair value techniques whenever events or changes in circumstances indicate a condition of impairment exists. The estimated fair value of prepaid expenses and other current assets, accounts payable and accrued expenses approximates their individual carrying amounts due to the short-term nature of these measurements. Cash and cash equivalents are stated at carrying value which approximates fair value.

ACCRUED EXPENSES

ACCRUED EXPENSES	9 Months Ended
	Jul. 31, 2021
Payables and Accruals [Abstract]
ACCRUED EXPENSES	5. ACCRUED EXPENSES Accrued expenses consist of the following as of: SCHEDULE OF ACCRUED EXPENSES July 31, 2021 October 31, 2020 Payroll and related expenses $ 392,376 $ 415,331 Accrued royalty and contingent legal fees 577,190 449,691 Accrued collaborative research and license expense - 30,000 Accrued other 20,158 6,003 Accrued expenses $ 989,724 $ 901,025

NET LOSS PER SHARE OF COMMON ST

NET LOSS PER SHARE OF COMMON STOCK	9 Months Ended
	Jul. 31, 2021
Earnings Per Share [Abstract]
NET LOSS PER SHARE OF COMMON STOCK	6. NET LOSS PER SHARE OF COMMON STOCK Basic net loss per common share (“Basic EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per common share (“Diluted EPS”) is computed by dividing net loss by the weighted average number of common shares and dilutive common share equivalents and convertible securities then outstanding. Diluted EPS for all periods presented is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculation of Diluted EPS for the nine months ended July 31, 2021 and 2020, were stock options to purchase 10,303,626 8,101,658 860,000 500,000

EFFECT OF RECENTLY ADOPTED AND

EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS	9 Months Ended
	Jul. 31, 2021
Effect Of Recently Adopted And Issued Pronouncements
EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS	7. EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2016-02 (“ASU 2016-02”) Accounting Standards Codification Topic 842, Leases (“ASC 842”), which supersedes Topic 840, Leases, and which requires lessees to recognize most leases on the balance sheet. The new lease standard does not substantially change lessor accounting. For public companies, the standard was effective for the first interim reporting period within annual periods beginning after December 15, 2018, although early adoption was permitted. Lessees and lessors were required to apply the new standard at the beginning of the earliest period presented in the financial statements in which they first apply the new guidance. In July 2018, FASB issued ASU 2018-11, Leases, which provides an additional transition option for an entity to apply the provisions of ASC 842 by recognizing a cumulative effect adjustment at the effective date of adoption without adjusting the prior comparative periods presented. The requirements of this standard include a significant increase in required disclosures. The Company adopted ASU 2016-02 on November 1, 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. See Note 9 regarding the accounting and disclosures related to our office lease. In January 2020, the FASB issued Accounting Standards Update 2020-01 (“ASU 2020-01”) Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The amendments in ASU 2020-01 clarify certain interactions between the guidance to account for certain equity securities under Topic 321, the guidance to account for investments under the equity method of accounting in Topic 323, and the guidance in Topic 815, which could change how an entity accounts for an equity security under the measurement alternative or a forward contract or purchased option to purchase securities that, upon settlement of the forward contract or exercise of the purchased option, would be accounted for under the equity method of accounting or the fair value option in accordance with Topic 825, Financial Instruments. These amendments improve current GAAP by reducing diversity in practice and increasing comparability of the accounting for these interactions. The amendments in this update are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The adoption of this standard will not have a material impact on our disclosures or consolidated financial statements.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Jul. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	8. INCOME TAXES We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. We have provided a full valuation allowance against our deferred tax asset due to our historical pre-tax losses and the uncertainty regarding the realizability of these deferred tax assets. We have substantial net operating loss carryforwards for Federal and California income tax returns. These net operating loss carryforwards could be subject to limitations under Internal Revenue Code section 382. We have no

LEASES

LEASES	9 Months Ended
	Jul. 31, 2021
Leases
LEASES	9. LEASES We lease approximately 2,000 September 30, 2021 5,000 3 16,000 16,000 48,000 48,000 On November 1, 2019, the Company adopted ASC 842, which increases transparency and comparability by recognizing a lessee’s rights and obligations resulting from leases by recording them on the balance sheet as lease assets and lease liabilities. The new guidance requires the recognition of the right-of-use (“ROU”) assets and related operating lease liabilities on the balance sheet. The Company adopted the new guidance using the modified retrospective approach on November 1, 2019. For operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments. The remaining 2 Balance sheet information related to the Company’s lease is presented below: SCHEDULE OF OPERATING LEASE Balance Sheet Location July 31, 2021 October 31, 2020 Operating Lease: Right-of-use asset Operating lease right-of-use asset $ 10,411 $ 54,340 Right-of-use liability, current Operating lease liability 10,567 55,198 As of July 31, 2021, the annual minimum lease payments of our operating lease liabilities were as follows: SCHEDULE OF MINIMUM LEASE PAYMENTS Operating Leases 2021 future minimum payments, undiscounted $ 10,752 Less: Imputed interest (185 ) Present value of future minimum lease payments $ 10,567 In August 2021 the lease was extended until September 30, 2024 under substantially the same terms as the existing lease.

COMMITMENTS AND CONTINGENCES

COMMITMENTS AND CONTINGENCES	9 Months Ended
	Jul. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCES	10. COMMITMENTS AND CONTINGENCES Litigation Matters We are not involved in any litigation or other legal proceedings and management is not aware of any pending litigation or legal proceeding against us that would have a material adverse effect upon our results of operations or financial condition. Impact of Coronavirus Pandemic On March 10, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The virus and actions taken to mitigate its spread have had and are expected to continue to have a broad adverse impact on the economies and financial markets of many countries, including the geographical areas in which the Company operates and conducts its business, and which the Company’s partners operate and conduct their business. We are currently following the recommendations of local health authorities to minimize exposure risk for our team members and visitors. However, while the outlook is improving, and there has been a loosening of restrictions in many of the areas in which we and our partners operate and conduct our business, the scale and scope of this pandemic is unknown, and the duration of the business disruption and related financial impact cannot be reasonably estimated at this time. While we have implemented specific business continuity plans to reduce the potential impact of COVID-19, there is no guarantee that our continuity plans will be successful. We have experienced certain disruptions to our business such as temporary closure of our offices and similar disruptions have occurred for our partners. Specifically, the outbreak has caused temporary shutdowns of the laboratories and other service providers that we rely on to develop our programs, and those laboratories and service providers that have been operating or that have begun operating recently have been doing so with more limited capacity due to social distancing requirements. As a result, our progress has been slowed and there is no assurance that we will be able to meet our previously announced timelines regarding the advancement of our programs. The extent to which COVID-19 or any other health epidemic may impact our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. Accordingly, COVID-19 could have a material adverse effect on our business, results of operations, financial condition and prospects.

SEGMENT INFORMATION

SEGMENT INFORMATION	9 Months Ended
	Jul. 31, 2021
Segment Reporting [Abstract]
SEGMENT INFORMATION	11. SEGMENT INFORMATION We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in five SCHEDULE OF SEGMENT INFORMATION 2021 2020 2021 2020 For the Three Months Ended For the Nine Months Ended 2021 2020 2021 2020 Net Income/(Loss): CAR-T Therapeutics $ (1,618,860 ) $ (417,502 ) $ (4,025,354 ) $ (1,542,865 ) Cancer Vaccines (1,464,323 ) (178,738 ) (3,033,026 ) (544,605 ) Anti-Viral Therapeutics (1,262,260 ) (281,098 ) (2,052,821 ) (590,602 ) Cancer Diagnostics (38,198 ) (1,693,304 ) (60,569 ) (5,162,977 ) Patent Licensing (3,969 ) (6,145 ) 114,894 (10,303 ) Total $ (4,387,610 ) $ (2,576,787 ) $ (9,056,876 ) $ (7,851,352 ) Net Income/(Loss) $ (4,387,610 ) $ (2,576,787 ) $ (9,056,876 ) $ (7,851,352 ) Total operating costs and expenses $ 4,388,236 $ 2,435,969 $ 9,571,149 $ 7,735,975 Less non-cash share-based compensation (3,187,326 ) (1,041,799 ) (5,224,697 ) (3,173,219 ) Operating costs and expenses $ 1,200,910 $ 1,394,170 $ 4,346,452 $ 4,562,756 Operating costs and expenses excluding CAR-T Therapeutics $ 411,313 $ 189,589 $ 1,903,707 $ 759,752 Cancer Vaccines 348,535 72,968 1,185,060 238,297 Anti-Viral Therapeutics 418,285 155,224 826,716 376,242 Cancer Diagnostics 20,645 971,698 37,368 3,180,511 Patent Licensing 2,132 4,691 393,601 7,954 Total $ 1,200,910 $ 1,394,170 4,346,452 $ 4,562,756 Operating costs and expenses excluding non-cash share-based compensation $ 1,200,910 $ 1,394,170 4,346,452 $ 4,562,756 July 31, October 31, Total assets: CAR-T Therapeutics $ 12,709,167 $ 2,988,124 Cancer Vaccines 10,706,026 946,923 Anti-Viral Therapeutics 12,849,445 2,464,361 Cancer Diagnostics 682,943 2,869,529 Patent Licensing 114,810 184,027 Total $ 37,062,391 $ 9,452,964 Total assets $ 37,062,391 $ 9,452,964 Operating costs and expenses excluding non-cash share-based compensation expense is the measurement the chief operating decision-maker uses in managing the enterprise.

BUSINESS AND FUNDING (Tables)

BUSINESS AND FUNDING (Tables)	9 Months Ended
	Jul. 31, 2021
Accounting Policies [Abstract]
SCHEDULE OF CHANGES IN NONCONTROLLING INTEREST	Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the nine months ended July 31, 2021: SCHEDULE OF CHANGES IN NONCONTROLLING INTEREST Balance, October 31, 2020 $ (496,983 ) Net loss attributable to noncontrolling interest (115,745 ) Balance, July 31, 2021 $ (612,728 )

STOCK BASED COMPENSATION (Table

STOCK BASED COMPENSATION (Tables)	9 Months Ended
	Jul. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
SCHEDULE OF OPTION ACTIVITY	Information regarding Non-Plan Options for the nine months ended July 31, 2021 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Options outstanding at October 31, 2020 1,698,000 $ 2.58 Exercised (44,000 ) $ 2.58 Options outstanding and exercisable at 1,654,000 $ 2.58 $ 3,051,630 Shares Weighted Aggregate Intrinsic Value Options outstanding at October 31, 2019 1,698,000 $ 2.58 Options outstanding and exercisable at 1,698,000 $ 2.58 $ 348,000
SCHEDULE OF OUTSTANDING AND EXERCISABLE	The following table summarizes information about Non-Plan Options outstanding and exercisable as of July 31, 2021: SCHEDULE OF OUTSTANDING AND EXERCISABLE Range of Number Weighted Average Remaining Contractual Life Weighted $ 2.58 1,654,000 1.06 $ 2.58 Range of Number Weighted Average Weighted $ 2.58 1,698,000 2.00 $ 2.58
2003 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
SCHEDULE OF OPTION ACTIVITY	Information regarding the 2003 Plan for the nine months ended July 31, 2020 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Options outstanding at October 31, 2019 400 $ 17.00 Granted - $ - Exercised                  - $ - Forfeited/Expired (400 ) $ 17.00 Options outstanding and exercisable at - $ - 0 $ - 0 Options outstanding at July 31, 2020 - $ - $ - Options exercisable at July 31, 2020 - $ - $ -
2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
SCHEDULE OF OPTION ACTIVITY	Information regarding the 2010 Share Plan for the nine months ended July 31, 2021 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Options outstanding at October 31, 2020 1,907,534 $ 2.82 Exercised                  (37,500 ) $ 2.40 Forfeited/Expired (10,400 ) $ 4.57 Options outstanding and exercisable at July 31, 2021 1,859,634 $ 2.82 $ 3,138,347 Shares Weighted Average Exercise Price Per Share Aggregate Options outstanding at October 31, 2019 1,998,668 $ 2.80 Exercised (51,100 ) $ 2.39 Forfeited/Expired (20,534 ) $ 1.72 Options outstanding at July 31, 2020 1,927,034 $ 2.82 $ 731,670 Options exercisable at July 31, 2020 1,772,034 $ 2.84 $ 630,120
SCHEDULE OF OUTSTANDING AND EXERCISABLE	The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of July 31, 2021: SCHEDULE OF OUTSTANDING AND EXERCISABLE Number And Exercisable Weighted Average (in years) Weighted $ 0 $ .67 2.30 527,500 4.80 $ 1.54 $ 2.58 3.13 818,000 2.65 $ 2.80 $ 3.46 5.30 514,134 6.75 $ 4.16 Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 0.67 2.30 549,000 5.70 $ 1.57 494,000 5.56 $ 1.64 $ 2.58 3.13 846,000 3.05 $ 2.79 846,000 3.41 $ 2.79 $ 3.46 5.75 532,034 7.45 $ 4.16 432,034 7.33 $ 4.33
2018 Share Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
SCHEDULE OF OPTION ACTIVITY	Information regarding the 2018 Share Plan for the nine months ended July 31, 2021 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Intrinsic Value Options outstanding at October 31, 2020 4,346,661 $ 3.69 Granted 4,370,000 $ 3.79 Exercised (33,888 ) $ 3.81 Forfeited/Expired (1,392,781 ) $ 3.70 Options outstanding at July 31, 2021 7,289,992 $ 3.74 $ 5,164,696 Options exercisable at July 31, 2021 2,914,586 $ 3.64 $ 2,328,335
2018 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
SCHEDULE OF OPTION ACTIVITY	Information regarding the 2018 Share Plan for the nine months ended July, 2020 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Intrinsic Value Options outstanding at October 31, 2019 3,935,000 $ 3.74 Granted 800,000 $ 3.85 Forfeited/Expired (258,376 ) $ 3.86 Options outstanding at July 31, 2020 4,476,624 $ 3.76 $ - 0 Options exercisable at July 31, 2020 2,403,014 $ 3.76 $ - 0
SCHEDULE OF OUTSTANDING AND EXERCISABLE	The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of July 31, 2021: SCHEDULE OF OUTSTANDING AND EXERCISABLE Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 2.09 3.70 2,975,000 7.90 $ 3.28 2,047,360 7.25 $ 3.49 $ 3.84 5.30 4,314,992 8.95 $ 4.06 867,226 7.33 $ 3.99 Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 3.70 3,100,000 7.78 $ 3.70 1,700,000 7.78 $ 3.70 $ 3.84 4.61 1,376,624 7.55 $ 3.89 703,014 6.15 $ 3.90

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Jul. 31, 2021
Fair Value Disclosures [Abstract]
SCHEDULE OF FAIR VALUE MEASUREMENTS	The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of July 31, 2021: SCHEDULE OF FAIR VALUE MEASUREMENTS Level 1 Level 2 Level 3 Total Money market funds: Cash and cash equivalents $ 26,807,696 $ - $ - $ 26,807,696 Certificates of deposit: Cash and cash equivalents 250,000 - - 250,000 Short-term investments - 1,000,000 - 1,000,000 Treasury bills and bonds: Short-term investments - 8,399,784 - 8,399,784 Total financial assets $ 27,057,696 $ 9,399,784 $ - $ 36,457,480 The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2020: Level 1 Level 2 Level 3 Total Money market funds: Cash and cash equivalents $ 3,902,292 $ - $ - $ 3,902,292 Certificates of deposit: Cash and cash equivalents 2,250,000 - - 2,250,000 Short-term investments - 2,640,000 - 2,640,000 Total financial assets $ 6,152,292 $ 2,640,000 $ - $ 8,792,292

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	9 Months Ended
	Jul. 31, 2021
Payables and Accruals [Abstract]
SCHEDULE OF ACCRUED EXPENSES	Accrued expenses consist of the following as of: SCHEDULE OF ACCRUED EXPENSES July 31, 2021 October 31, 2020 Payroll and related expenses $ 392,376 $ 415,331 Accrued royalty and contingent legal fees 577,190 449,691 Accrued collaborative research and license expense - 30,000 Accrued other 20,158 6,003 Accrued expenses $ 989,724 $ 901,025

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Jul. 31, 2021
Leases
SCHEDULE OF OPERATING LEASE	Balance sheet information related to the Company’s lease is presented below: SCHEDULE OF OPERATING LEASE Balance Sheet Location July 31, 2021 October 31, 2020 Operating Lease: Right-of-use asset Operating lease right-of-use asset $ 10,411 $ 54,340 Right-of-use liability, current Operating lease liability 10,567 55,198
SCHEDULE OF MINIMUM LEASE PAYMENTS	As of July 31, 2021, the annual minimum lease payments of our operating lease liabilities were as follows: SCHEDULE OF MINIMUM LEASE PAYMENTS Operating Leases 2021 future minimum payments, undiscounted $ 10,752 Less: Imputed interest (185 ) Present value of future minimum lease payments $ 10,567

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	9 Months Ended
	Jul. 31, 2021
Segment Reporting [Abstract]
SCHEDULE OF SEGMENT INFORMATION	SCHEDULE OF SEGMENT INFORMATION 2021 2020 2021 2020 For the Three Months Ended For the Nine Months Ended 2021 2020 2021 2020 Net Income/(Loss): CAR-T Therapeutics $ (1,618,860 ) $ (417,502 ) $ (4,025,354 ) $ (1,542,865 ) Cancer Vaccines (1,464,323 ) (178,738 ) (3,033,026 ) (544,605 ) Anti-Viral Therapeutics (1,262,260 ) (281,098 ) (2,052,821 ) (590,602 ) Cancer Diagnostics (38,198 ) (1,693,304 ) (60,569 ) (5,162,977 ) Patent Licensing (3,969 ) (6,145 ) 114,894 (10,303 ) Total $ (4,387,610 ) $ (2,576,787 ) $ (9,056,876 ) $ (7,851,352 ) Net Income/(Loss) $ (4,387,610 ) $ (2,576,787 ) $ (9,056,876 ) $ (7,851,352 ) Total operating costs and expenses $ 4,388,236 $ 2,435,969 $ 9,571,149 $ 7,735,975 Less non-cash share-based compensation (3,187,326 ) (1,041,799 ) (5,224,697 ) (3,173,219 ) Operating costs and expenses $ 1,200,910 $ 1,394,170 $ 4,346,452 $ 4,562,756 Operating costs and expenses excluding CAR-T Therapeutics $ 411,313 $ 189,589 $ 1,903,707 $ 759,752 Cancer Vaccines 348,535 72,968 1,185,060 238,297 Anti-Viral Therapeutics 418,285 155,224 826,716 376,242 Cancer Diagnostics 20,645 971,698 37,368 3,180,511 Patent Licensing 2,132 4,691 393,601 7,954 Total $ 1,200,910 $ 1,394,170 4,346,452 $ 4,562,756 Operating costs and expenses excluding non-cash share-based compensation $ 1,200,910 $ 1,394,170 4,346,452 $ 4,562,756 July 31, October 31, Total assets: CAR-T Therapeutics $ 12,709,167 $ 2,988,124 Cancer Vaccines 10,706,026 946,923 Anti-Viral Therapeutics 12,849,445 2,464,361 Cancer Diagnostics 682,943 2,869,529 Patent Licensing 114,810 184,027 Total $ 37,062,391 $ 9,452,964 Total assets $ 37,062,391 $ 9,452,964

SCHEDULE OF CHANGES IN NONCONTR

SCHEDULE OF CHANGES IN NONCONTROLLING INTEREST (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2021	Jul. 31, 2020	Jul. 31, 2021	Jul. 31, 2020
Accounting Policies [Abstract]
Balance			$ (496,983)
Net loss attributable to noncontrolling interest	$ (53,621)	$ (15,103)	(115,745)	$ (57,032)
Balance	$ (612,728)		$ (612,728)

BUSINESS AND FUNDING (Details N

BUSINESS AND FUNDING (Details Narrative) - USD ($)	Mar. 25, 2021	Jul. 31, 2021	Jul. 31, 2020
Entity Listings [Line Items]
Proceeds from issuance common stock		$ 11,174,490	$ 8,180,112
At-the-Market Equity Program [Member]
Entity Listings [Line Items]
Proceeds from issuance common stock		$ 10,834,000
Sale of shares of common stock		2,806,410
Public Offering [Member]
Entity Listings [Line Items]
Ownership percentage	15.80%
Proceeds from issuance common stock	$ 20,292,000	$ 20,292,000
Sale of shares of common stock	4,285,715	4,285,715
Wistar Institute [Member]
Entity Listings [Line Items]
Ownership percentage		5.00%

PUBLIC OFFERING (Details Narrat

PUBLIC OFFERING (Details Narrative) - USD ($)	Mar. 25, 2021	Jul. 31, 2021	Jul. 31, 2020	Oct. 30, 2020
Subsidiary, Sale of Stock [Line Items]
Proceeds from issuance common stock		$ 11,174,490	$ 8,180,112
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants maturity date		Nov. 30, 2021
Warrants to purchase common stock		500,000
Warrants to purchase common stock per share		$ 5.03		$ 2.06
Public Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of shares of common stock	4,285,715	4,285,715
Ownership percentage	15.80%
Sale of stock price per share	$ 5.25
Proceeds from issuance common stock	$ 20,292,000	$ 20,292,000
Public Offering [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants maturity date	Mar. 22, 2026
Warrants to purchase common stock	300,000
Warrants to purchase common stock per share	$ 6.5625

SCHEDULE OF OPTION ACTIVITY (De

SCHEDULE OF OPTION ACTIVITY (Details) - USD ($)	9 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Options outstanding, Beginning balance	1,698,000	1,698,000
Weighted Average Exercise Price Per Share, Outstanding Beginning balance	$ 2.58	$ 2.58
Shares, Options, Exercised	(44,000)
Weighted Average Exercise Price Per Share, Exercised	$ 2.58
Shares, Options outstanding and Exercisable	1,654,000	1,698,000
Weighted Average Exercise Price Per Share, Outstanding and Exercisable	$ 2.58	$ 2.58
Aggregate Intrinsic Value, Outstanding and Exercisable	$ 3,051,630	$ 348,000
Aggregate Intrinsic Value, Outstanding and Exercisable	3,051,630	$ 348,000
Weighted Average Exercise Price Per Share, Outstanding Ending balance
2003 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Options outstanding, Beginning balance		400
Weighted Average Exercise Price Per Share, Outstanding Beginning balance		$ 17
Shares, Options, Granted
Weighted Average Exercise Price Per Share, Granted
Shares, Options, Exercised
Weighted Average Exercise Price Per Share, Exercised
Shares, Options, Forfeited/Expired		(400)
Weighted Average Exercise Price Per Share, Forfeited/Expired		$ 17
Shares, Options outstanding and Exercisable
Weighted Average Exercise Price Per Share, Outstanding and Exercisable		$ 0
Aggregate Intrinsic Value, Outstanding and Exercisable	3,138,347	$ 0
Shares, Options outstanding, Ending balance
Weighted Average Exercise Price Per Share, Outstanding Ending balance
Aggregate Intrinsic Value, Outstanding Ending balance
Shares, Options outstanding, Exercisable
Weighted Average Exercise Price Per Share, Exercisable
Aggregate Intrinsic Value, Exercisable
Aggregate Intrinsic Value, Outstanding and Exercisable	$ 3,138,347	$ 0
Weighted Average Exercise Price Per Share, Outstanding Ending balance
Weighted Average Exercise Price Per Share, Exercisable
2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Options outstanding, Beginning balance	1,907,534	1,998,668
Weighted Average Exercise Price Per Share, Outstanding Beginning balance	$ 2.82	$ 2.80
Shares, Options, Exercised	(37,500)	(51,100)
Weighted Average Exercise Price Per Share, Exercised	$ 2.40	$ 2.39
Shares, Options, Forfeited/Expired	(10,400)	(20,534)
Weighted Average Exercise Price Per Share, Forfeited/Expired	$ 4.57	$ 1.72
Shares, Options outstanding and Exercisable	1,859,634
Weighted Average Exercise Price Per Share, Outstanding and Exercisable	$ 2.82
Shares, Options outstanding, Ending balance		1,927,034
Weighted Average Exercise Price Per Share, Outstanding Ending balance		$ 2.82
Aggregate Intrinsic Value, Outstanding Ending balance		$ 731,670
Shares, Options outstanding, Exercisable		1,772,034
Weighted Average Exercise Price Per Share, Exercisable		$ 2.84
Aggregate Intrinsic Value, Exercisable		$ 630,120
Weighted Average Exercise Price Per Share, Outstanding Ending balance		$ 2.82
Weighted Average Exercise Price Per Share, Exercisable		$ 2.84
2018 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Options outstanding, Beginning balance	4,346,661	3,935,000
Weighted Average Exercise Price Per Share, Outstanding Beginning balance	$ 3.69	$ 3.74
Shares, Options, Granted	4,370,000	800,000
Weighted Average Exercise Price Per Share, Granted	$ 3.79	$ 3.85
Shares, Options, Exercised	(33,888)
Weighted Average Exercise Price Per Share, Exercised	$ 3.81
Shares, Options, Forfeited/Expired	(1,392,781)	(258,376)
Weighted Average Exercise Price Per Share, Forfeited/Expired	$ 3.70	$ 3.86
Shares, Options outstanding, Ending balance	7,289,992	4,476,624
Weighted Average Exercise Price Per Share, Outstanding Ending balance	$ 3.74	$ 3.76
Aggregate Intrinsic Value, Outstanding Ending balance	$ 5,164,696	$ 0
Shares, Options outstanding, Exercisable	2,914,586	2,403,014
Weighted Average Exercise Price Per Share, Exercisable	$ 3.64	$ 3.76
Aggregate Intrinsic Value, Exercisable	$ 2,328,335	$ 0
Weighted Average Exercise Price Per Share, Outstanding Ending balance	$ 3.74	$ 3.76
Weighted Average Exercise Price Per Share, Exercisable	$ 3.64	$ 3.76

SCHEDULE OF OUTSTANDING AND EXE

SCHEDULE OF OUTSTANDING AND EXERCISABLE (Details) - $ / shares	9 Months Ended
	Jul. 31, 2021	Jul. 31, 2020	Oct. 31, 2020	Oct. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Outstanding			1,698,000	1,698,000
Weighted Average Exercise Price			$ 2.58	$ 2.58
2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Outstanding		1,927,034	1,907,534	1,998,668
Weighted Average Exercise Price		$ 2.82	$ 2.82	$ 2.80
Number Exercisable, Options Exercisable		1,772,034
Weighted Average Exercise Price, Options Exercisable		$ 2.84
2010 Plan [Member] | Range 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, Lower limit	$ 0.67	0.67
Range of Exercise Prices, Upper limit	$ 2.30	$ 2.30
Number of Outstanding	527,500	549,000
Weighted Average Remaining Contractual Life (in years)	4 years 9 months 18 days	5 years 8 months 12 days
Weighted Average Exercise Price	$ 1.54	$ 1.57
Number Exercisable, Options Exercisable		494,000
Weighted Average Remaining Contractual Life (in years), Options Exercisable		5 years 6 months 21 days
Weighted Average Exercise Price, Options Exercisable		$ 1.64
2010 Plan [Member] | Range 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, Lower limit	2.58	2.58
Range of Exercise Prices, Upper limit	$ 3.13	$ 3.13
Number of Outstanding	818,000	846,000
Weighted Average Remaining Contractual Life (in years)	2 years 7 months 24 days	3 years 18 days
Weighted Average Exercise Price	$ 2.80	$ 2.79
Number Exercisable, Options Exercisable		846,000
Weighted Average Remaining Contractual Life (in years), Options Exercisable		3 years 4 months 28 days
Weighted Average Exercise Price, Options Exercisable		$ 2.79
2010 Plan [Member] | Range 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, Lower limit	3.46	3.46
Range of Exercise Prices, Upper limit	$ 5.30	$ 5.75
Number of Outstanding	514,134	532,034
Weighted Average Remaining Contractual Life (in years)	6 years 9 months	7 years 5 months 12 days
Weighted Average Exercise Price	$ 4.16	$ 4.16
Number Exercisable, Options Exercisable		432,034
Weighted Average Remaining Contractual Life (in years), Options Exercisable		7 years 3 months 29 days
Weighted Average Exercise Price, Options Exercisable		$ 4.33
2018 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Outstanding	7,289,992	4,476,624	4,346,661	3,935,000
Weighted Average Exercise Price	$ 3.74	$ 3.76	$ 3.69	$ 3.74
Number Exercisable, Options Exercisable	2,914,586	2,403,014
Weighted Average Exercise Price, Options Exercisable	$ 3.64	$ 3.76
2018 Plan [Member] | Range 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, Lower limit	2.09
Range of Exercise Prices, Upper limit	$ 3.70
Number of Outstanding	2,975,000	3,100,000
Weighted Average Remaining Contractual Life (in years)	7 years 10 months 24 days	7 years 9 months 10 days
Weighted Average Exercise Price	$ 3.28	$ 3.70
Number Exercisable, Options Exercisable	2,047,360	1,700,000
Weighted Average Remaining Contractual Life (in years), Options Exercisable	7 years 3 months	7 years 9 months 10 days
Weighted Average Exercise Price, Options Exercisable	$ 3.49	$ 3.70
Range of Exercise Prices		3.70
2018 Plan [Member] | Range 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, Lower limit	3.84	$ 3.84
Range of Exercise Prices, Upper limit	$ 5.30	$ 4.61
Number of Outstanding	4,314,992	1,376,624
Weighted Average Remaining Contractual Life (in years)	8 years 11 months 12 days	7 years 6 months 18 days
Weighted Average Exercise Price	$ 4.06	$ 3.89
Number Exercisable, Options Exercisable	867,226	703,014
Weighted Average Remaining Contractual Life (in years), Options Exercisable	7 years 3 months 29 days	6 years 1 month 24 days
Weighted Average Exercise Price, Options Exercisable	$ 3.99	$ 3.90
Outside of Plans [Member] | Range 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Remaining Contractual Life (in years)	1 year 21 days	2 years
Weighted Average Exercise Price	$ 2.58	$ 2.58
Range of Exercise Prices	2.58	2.58
Number of Options Outstanding and Exercisable	1,654,000	1,698,000

STOCK BASED COMPENSATION (Detai

STOCK BASED COMPENSATION (Details Narrative)	Jun. 01, 2021$ / sharesshares	Oct. 30, 2020$ / sharesshares	May 08, 2018$ / sharesshares	Oct. 31, 2018Days$ / sharesshares	Jul. 31, 2021USD ($)$ / sharesshares	Jul. 31, 2020USD ($)shares	Jul. 31, 2021USD ($)$ / sharesshares	Jul. 31, 2020USD ($)shares	Mar. 25, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option compensation to employees and directors | $							$ 4,803,515	$ 3,016,305
Weighted average exercise per share | $ / shares							$ 2.58
Stock options exercised, shares							44,000
Stock options exercised | $						$ 18,540	$ 293,604	122,270
Proceeds from stock plans | $							$ 3,000	15,452
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		5 months
Class of Warrant or Right, Date from which Warrants or Rights Exercisable		Oct. 30, 2025
[custom:WarrantsPurchaseOfCommonStock-0]		60,000
Warrant exercise price | $ / shares		$ 2.06			$ 5.03		$ 5.03
[custom:ConsultingExpense] | $							$ 96,000	$ 0
Warrants to purchase common stock					500,000		500,000
Warrants maturity date					Nov. 30, 2021		Nov. 30, 2021
Warrants issued						0		0
Warrant [Member] | Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant exercise price | $ / shares									$ 6.5625
Warrants to purchase common stock									300,000
Warrants maturity date									Mar. 22, 2026
2018 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise per share | $ / shares							$ 3.81
Shares options, granted							4,370,000	800,000
Stock options exercised, shares							33,888
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					1,257,937		1,257,937
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option to purchase common stock					0	0	107,451	107,451
Stock options exercised, shares					7,200	7,200	51,100	51,100
Stock options exercised | $					$ 0	$ 19,000	$ 294,000	$ 122,000
Shares withheld on a cashless exercise							7,937	7,937
Equity Option [Member] | 2018 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares options, granted	100,000
Market Conditions Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option compensation to employees and directors | $					1,981,000
Non Vested Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option compensation to employees and directors | $					4,528,000
Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option to purchase common stock				500,000
Weighted average exercise per share | $ / shares				$ 5
Consecutive trading days | Days				20
Minimum [Member] | Equity Option [Member] | 2018 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise per share | $ / shares	$ 5
Maximum [Member] | Equity Option [Member] | 2018 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise per share | $ / shares	$ 8
Shares options, granted	2,000,000
Employees and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option compensation to employees and directors | $					1,066,000	997,000	$ 2,822,000	$ 3,016,000
Employees and Directors [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							1 year
Employees and Directors [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							4 years
Chairman, President and Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option to purchase common stock			1,500,000
Expiration date			May 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate							1.62%
Chairman, President and Chief Executive Officer [Member] | Market Conditions Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares options, granted							4.02
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term							10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate							75.00%
Chairman, President and Chief Executive Officer [Member] | Restricted Stock [Member] | 2018 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option to purchase common stock			1,500,000
Weighted average exercise per share | $ / shares			$ 11
Expiration date			May 31, 2021
Chairman, President and Chief Executive Officer [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise per share | $ / shares			$ 5
Service period			3 months
Chairman, President and Chief Executive Officer [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise per share | $ / shares			$ 8
Service period			7 months
Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option compensation to employees and directors | $					$ 139,000	$ 45,000	$ 326,000	$ 157,000
Employees and Consultants [Member] | 2018 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares options, granted					2,990,000	0	4,370,000	800,000
Employees and Consultants [Member] | Minimum [Member] | 2018 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares					$ 2.83		$ 2.83
Employees and Consultants [Member] | Maximum [Member] | 2018 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares					$ 5.30		$ 5.30
Employees [Member] | Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option to purchase common stock							1,634	9,618
Purchase price of common stock percentage							85.00%
Proceeds from stock plans | $							$ 3,000	$ 15,000

SCHEDULE OF FAIR VALUE MEASUREM

SCHEDULE OF FAIR VALUE MEASUREMENTS (Details) - USD ($)	Jul. 31, 2021	Oct. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds: Cash and cash equivalents	$ 26,807,696	$ 3,902,292
Certificates of deposit: Cash and cash equivalents	250,000	2,250,000
Certificates of deposit: Short-term investments	1,000,000	2,640,000
Treasury bills and bonds: Short-term investments	8,399,784
Total financial assets	36,457,480	8,792,292
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds: Cash and cash equivalents	26,807,696	3,902,292
Certificates of deposit: Cash and cash equivalents	250,000	2,250,000
Certificates of deposit: Short-term investments
Treasury bills and bonds: Short-term investments
Total financial assets	27,057,696	6,152,292
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds: Cash and cash equivalents
Certificates of deposit: Cash and cash equivalents
Certificates of deposit: Short-term investments	1,000,000	2,640,000
Treasury bills and bonds: Short-term investments	8,399,784
Total financial assets	9,399,784	2,640,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds: Cash and cash equivalents
Certificates of deposit: Cash and cash equivalents
Certificates of deposit: Short-term investments
Treasury bills and bonds: Short-term investments
Total financial assets

SCHEDULE OF ACCRUED EXPENSES (D

SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($)	Jul. 31, 2021	Oct. 31, 2020
Payables and Accruals [Abstract]
Payroll and related expenses	$ 392,376	$ 415,331
Accrued royalty and contingent legal fees	577,190	449,691
Accrued collaborative research and license expense		30,000
Accrued other	20,158	6,003
Accrued expenses	$ 989,724	$ 901,025

NET LOSS PER SHARE OF COMMON _2

NET LOSS PER SHARE OF COMMON STOCK (Details Narrative) - shares	9 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	10,303,626	8,101,658
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	860,000	500,000

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	Jul. 31, 2021	Oct. 31, 2020
Income Tax Disclosure [Abstract]
Unrecognized income tax benefits, penalties	$ 0	$ 0

SCHEDULE OF OPERATING LEASE (De

SCHEDULE OF OPERATING LEASE (Details) - USD ($)	Jul. 31, 2021	Oct. 31, 2020
Leases
Right-of-use asset	$ 10,411	$ 54,340
Right-of-use liability, current	$ 10,567	$ 55,198

SCHEDULE OF MINIMUM LEASE PAYME

SCHEDULE OF MINIMUM LEASE PAYMENTS (Details)	Jul. 31, 2021USD ($)
Leases
2021 future minimum payments, undiscounted	$ 10,752
Less: Imputed interest	(185)
Present value of future minimum lease payments	$ 10,567

LEASES (Details Narrative)

LEASES (Details Narrative)	1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 31, 2021	Jul. 31, 2021USD ($)ft²	Jul. 31, 2020USD ($)	Jul. 31, 2021USD ($)ft²	Jul. 31, 2020USD ($)
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Rent expenses		$ 16,000	$ 16,000	$ 48,000	$ 48,000
Subsequent Event [Member]
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Lease extension	In August 2021 the lease was extended until September 30, 2024 under substantially the same terms as the existing lease.
Almaden Expressway, San Jose [Member]
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Area of land | ft²		2,000		2,000
Operating lease, expiration date				Sep. 30, 2021
Rent expenses				$ 5,000
Percentage of annual increase in rent				3.00%
Operating lease remaining term		2 months		2 months

SCHEDULE OF SEGMENT INFORMATION

SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2021	Jul. 31, 2020	Jul. 31, 2021	Jul. 31, 2020	Oct. 31, 2020
Segment Reporting Information [Line Items]
Net Income/(Loss)	$ (4,387,610)	$ (2,576,787)	$ (9,056,876)	$ (7,851,352)
Total operating costs and expenses	4,388,236	2,435,969	9,571,149	7,735,975
Less non-cash share-based compensation	(3,187,326)	(1,041,799)	(5,224,697)	(3,173,219)
Operating costs and expenses excluding non-cash share-based compensation	1,200,910	1,394,170	4,346,452	4,562,756
Total assets	37,062,391		37,062,391		$ 9,452,964
CAR-T Therapeutics [Member]
Segment Reporting Information [Line Items]
Net Income/(Loss)	(1,618,860)	(417,502)	(4,025,354)	(1,542,865)
Operating costs and expenses excluding non-cash share-based compensation	411,313	189,589	1,903,707	759,752
Total assets	12,709,167		12,709,167		2,988,124
Cancer Vaccines [Member]
Segment Reporting Information [Line Items]
Net Income/(Loss)	(1,464,323)	(178,738)	(3,033,026)	(544,605)
Operating costs and expenses excluding non-cash share-based compensation	348,535	72,968	1,185,060	238,297
Total assets	10,706,026		10,706,026		946,923
Anti-Viral Therapeutics [Member]
Segment Reporting Information [Line Items]
Net Income/(Loss)	(1,262,260)	(281,098)	(2,052,821)	(590,602)
Operating costs and expenses excluding non-cash share-based compensation	418,285	155,224	826,716	376,242
Total assets	12,849,445		12,849,445		2,464,361
Cancer Diagnostics [Member]
Segment Reporting Information [Line Items]
Net Income/(Loss)	(38,198)	(1,693,304)	(60,569)	(5,162,977)
Operating costs and expenses excluding non-cash share-based compensation	20,645	971,698	37,368	3,180,511
Total assets	682,943		682,943		2,869,529
Patent Licensing [Member]
Segment Reporting Information [Line Items]
Net Income/(Loss)	(3,969)	(6,145)	114,894	(10,303)
Operating costs and expenses excluding non-cash share-based compensation	2,132	$ 4,691	393,601	$ 7,954
Total assets	$ 114,810		$ 114,810		$ 184,027

SEGMENT INFORMATION (Details Na

SEGMENT INFORMATION (Details Narrative)	9 Months Ended
	Jul. 31, 2021Numbers
Segment Reporting [Abstract]
Number of Reportable Segments	5